Edge Therapeutics Obtains $10 Million Venture Loan Facility with Hercules Technology Growth Capital

BERKELEY HEIGHTS, N.J.– September 8, 2014 – Edge Therapeutics, a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological conditions, today announced that it has obtained up to $10 million in venture debt financing from Hercules Technology Growth Capital, Inc. (NYSE: HTGC), to support the continued development of EG-1962, the Company’s lead product candidate.

This entry was posted in Recent Development News: Q3 – 2014. Bookmark the permalink.